Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654718 | 0.82 | TRPV4 (0.38) | TRPV4CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL185550 | 0.82 | TRPV4 (0.38) | TRPV4CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL57346 | 0.81 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL30919072 | 0.81 | TRPV4 (0.61) | TRPV4CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL573864 | 0.78 | MAOB (0.53) | TRPV4CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL18105636 | 0.78 | TRPV4 (0.36) | TRPV4CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL8863193 | 0.78 | TRPV4 (0.37) | TRPV4CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL9725139 | 0.77 | PKM (0.38) | PKMCYP1A2KDM4EALDH1A1KMT2A | |
| SCHEMBL1343170 | 0.76 | MAOB (0.48) | TRPV4CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL21131569 | 0.76 | TRPV4 (0.45) | TRPV4CYP11B2CYP11B1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 594 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109265352-B | Preparation method of aryl cyclopropyl ether and derivatives thereof | 杭州迈世腾药物科技有限公司 | 2021-06-04 | — | — | CN | claimed |
| EP-3478657-B1 | DICARBAZOLBIPHENYLDERIVATIVES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-04-21 | — | — | EP | claimed |
| EP-3478657-A1 | DICARBAZOLBIPHENY DERIVATES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-05-08 | — | — | EP | claimed |
| CN-109415316-A | Dicarbazole Biphenyl Derivatives for Optoelectronic Devices | 辛诺拉有限公司 | 2019-03-01 | — | — | CN | claimed |
| CN-109265352-A | The preparation method of aryl cyclopropyl ether and its derivative | 杭州迈世腾药物科技有限公司 | 2019-01-25 | — | — | CN | claimed |
| WO-2018001821-A1 | DICARBAZOLBIPHENY DERIVATES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-01-04 | — | — | WO | claimed |
| EP-2069325-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | Serenex, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | ESANEX, INC. | 2008-03-20 | — | — | US | claimed |
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | claimed |
| WO-2008024977-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2008024961-A1 | DIHYDROPYRIDAZINE, TETRAHYDROPYRIDINE, CHROMANONE, AND DIHYDRONAPHTHALENONE DERIVATIVES AS HEAT-SHOCK PROTEIN 90 INHIBITORS | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| EP-4121421-B1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-12565497-B2 | Sulfone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-03-03 | — | — | US | disclosed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-12428370-B2 | Haloallylamine dual amine oxidase inhibitors | SYNTARA LIMITED (AU) | 2025-09-30 | — | — | US | disclosed |
| WO-2002076983-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002074772-A1 | IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
| US-4071570-A | ANTIARRHYTHMIC AGENTS | MERCK & CO., INC. (US) | 1978-01-31 | — | — | US | disclosed |
| US-3978127-A | ANTIARRHYTHMIC | MERCK & CO., INC. (US) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | QDPR, CCND2, CCND1 | TRPV4 961/4885CYP11B2 293/4885CYP11B1 241/4885 |
| US-12428370-B2 | Haloallylamine dual amine oxidase inhibitors | AOC2, AOC3, AOC1 | TRPV4 4015/4885CYP11B2 2470/4885CYP11B1 2518/4885 |
| US-20080070935-A1 | Isoquinoline, Quinazoline and Phthalazine Derivatives | H1-5, NDUFS5, IL5 | TRPV4 3020/4885CYP11B2 921/4885CYP11B1 944/4885 |
| US-12565497-B2 | Sulfone derivatives | CXCR1, CCR1, SULT1E1 | TRPV4 2973/4885CYP11B2 90/4885CYP11B1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.